Breast cancer--loss of PTEN predicts resistance to treatment - PubMed (original) (raw)

. 2004 Nov 25;351(22):2337-8.

doi: 10.1056/NEJMcibr043143.

Affiliations

• PMID: 15564551
• DOI: 10.1056/NEJMcibr043143

Breast cancer--loss of PTEN predicts resistance to treatment

Pier Paolo Pandolfi. N Engl J Med. 2004.

No abstract available

PubMed Disclaimer

Similar articles

• Successful targeting of ErbB2 receptors-is PTEN the key?
  Crowder RJ, Lombardi DP, Ellis MJ. Crowder RJ, et al. Cancer Cell. 2004 Aug;6(2):103-4. doi: 10.1016/j.ccr.2004.08.001. Cancer Cell. 2004. PMID: 15324690
• PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.
  Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D. Nagata Y, et al. Cancer Cell. 2004 Aug;6(2):117-27. doi: 10.1016/j.ccr.2004.06.022. Cancer Cell. 2004. PMID: 15324695
• PTEN activation may contribute to exquisite antitumor response to trastuzumab.
  Altundag K, Altundag O, Morandi P, Gunduz M. Altundag K, et al. Breast. 2005 Apr;14(2):175; author reply 176. doi: 10.1016/j.breast.2004.09.009. Breast. 2005. PMID: 15767191 No abstract available.
• Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
  Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Nahta R, et al. Nat Clin Pract Oncol. 2006 May;3(5):269-80. doi: 10.1038/ncponc0509. Nat Clin Pract Oncol. 2006. PMID: 16683005 Review.
• Trastuzumab: mechanisms of resistance and therapeutic opportunities.
  Calabrich A, Fernandes Gdos S, Katz A. Calabrich A, et al. Oncology (Williston Park). 2008 Oct;22(11):1250-8; discussion 1259, 1263. Oncology (Williston Park). 2008. PMID: 18980023 Review.

Cited by

• miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer.
  Cabello P, Torres-Ruiz S, Adam-Artigues A, Forés-Martos J, Martínez MT, Hernando C, Zazo S, Madoz-Gúrpide J, Rovira A, Burgués O, Rojo F, Albanell J, Lluch A, Bermejo B, Cejalvo JM, Eroles P. Cabello P, et al. Cancers (Basel). 2023 Apr 4;15(7):2138. doi: 10.3390/cancers15072138. Cancers (Basel). 2023. PMID: 37046799 Free PMC article.
• Nanoparticles (NPs)-mediated systemic mRNA delivery to reverse trastuzumab resistance for effective breast cancer therapy.
  Dong Z, Huang Z, Li S, Wang Y, Yao Y, Yang X, Xu X. Dong Z, et al. Acta Pharm Sin B. 2023 Mar;13(3):955-966. doi: 10.1016/j.apsb.2022.09.021. Epub 2022 Oct 4. Acta Pharm Sin B. 2023. PMID: 36970191 Free PMC article.
• Metabolic Biomarkers in B-Cell Lymphomas for Early Diagnosis and Prediction, as Well as Their Influence on Prognosis and Treatment.
  Alfaifi A, Bahashwan S, Alsaadi M, Malhan H, Aqeel A, Al-Kahiry W, Almehdar H, Qadri I. Alfaifi A, et al. Diagnostics (Basel). 2022 Feb 3;12(2):394. doi: 10.3390/diagnostics12020394. Diagnostics (Basel). 2022. PMID: 35204484 Free PMC article. Review.
• The PTEN and ATM axis controls the G1/S cell cycle checkpoint and tumorigenesis in HER2-positive breast cancer.
  Bassi C, Fortin J, Snow BE, Wakeham A, Ho J, Haight J, You-Ten A, Cianci E, Buckler L, Gorrini C, Stambolic V, Mak TW. Bassi C, et al. Cell Death Differ. 2021 Nov;28(11):3036-3051. doi: 10.1038/s41418-021-00799-8. Epub 2021 May 31. Cell Death Differ. 2021. PMID: 34059798 Free PMC article.

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program